Puma Biotechnology (PBYI) FCF Margin (2017 - 2026)
Puma Biotechnology's (PBYI) quarterly FCF Margin came in at 34.4% in Q1 2026, up 2668.0% YoY from 1.24% in Q1 2025, and up 79.56% on a QoQ basis from 19.16% in Q4 2025.
Puma Biotechnology (PBYI) FCF Margin (2017 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 10 years of FCF Margin data on file, last reported at 34.4% in Q1 2026.
- Quarterly FCF Margin rose 2668.0% year-over-year to 34.4% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23.59% (up 1020.0% YoY) and the FY2025 annual result came in at 18.27%, up 141.0% from the prior year.
- FCF Margin advanced to 34.4% in Q1 2026, from 19.16% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 34.4% in Q1 2026 to a low of 58.8% in Q1 2022.
- A 5-year average of 10.3% and a median of 14.45% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin slumped 7476 bps — and 2023, when it surged 6381 bps.
- Tracing PBYI's FCF Margin over 5 years: stood at 8.77% in 2022, then surged by 65 bps to 14.45% in 2023, then jumped by 82 bps to 26.36% in 2024, then declined by 27 bps to 19.16% in 2025, then surged by 80 bps to 34.4% in 2026.
- The last three FCF Margin figures came in at 34.4% (Q1 2026), 19.16% (Q4 2025), and 17.61% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 2.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.87% |
| Mar 31, 2026 | 34.40% |
| Dec 31, 2025 | 19.16% |
| Sep 30, 2025 | 17.61% |
| Jun 30, 2025 | 26.95% |
| Mar 31, 2025 | 7.72% |
| Dec 31, 2024 | 26.36% |
| Sep 30, 2024 | 13.69% |
| Jun 30, 2024 | 2.16% |
| Mar 31, 2024 | 25.70% |
| Dec 31, 2023 | 14.45% |
| Sep 30, 2023 | 18.94% |
| Jun 30, 2023 | 6.04% |
| Mar 31, 2023 | 5.01% |
| Dec 31, 2022 | 8.77% |
| Sep 30, 2022 | 30.22% |
| Jun 30, 2022 | -23.31% |
| Mar 31, 2022 | -58.80% |
| Dec 31, 2021 | -9.82% |
| Sep 30, 2021 | 22.70% |